title: Infliximab as the First Retreatment in Patients with Kawasaki Disease Resistant to Initial Intravenous Immunoglobulin.
abstract: Forty-three patients with Kawasaki disease who were resistant to initial intravenous immunoglobulin (IVIG) were randomized to receive either a second dose of IVIG (n = 32) or an infliximab (n = 11). With IVIG retreatment 21 patients (65.6%) responded, and with infliximab 10 patients (90.9%) responded. The infliximab group had shorter duration of fever and fewer days of hospitalization. Coronary artery outcomes and adverse events were similar.
authors.affiliation: From the Department of Pediatrics, Ewha Womans University School of Medicine, Seoul, Korea.
authors.forename: Youngmin
authors.initials: Y
authors.lastname: Youn
authors.forename: Jisoo
authors.initials: J
authors.lastname: Kim
authors.forename: Young Mi
authors.initials: YM
authors.lastname: Hong
authors.forename: Sejung
authors.initials: S
authors.lastname: Sohn
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003331:Coronary Vessels / Q000473:pathology; D004351:Drug Resistance; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007223:Infant; D000069285:Infliximab / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009080:Mucocutaneous Lymph Node Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D019233:Retreatment; D016896:Treatment Outcome
chemical_list: D016756:Immunoglobulins, Intravenous; D000069285:Infliximab